title: Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
abstract: Predicting the magnitude of potential drug-drug interactions is important for underwriting patient safety in the clinical setting. Substrate-dependent inhibition of cytochrome P450 enzymes may confound extrapolation of in vitro results to the in vivo situation. However, the potential for substrate-dependent inhibition with CYP2D6 has not been well characterized. The inhibition profiles of 20 known inhibitors of CYP2D6 were characterized in vitro against four clinically relevant CYP2D6 substrates (desipramine, dextromethorphan, metoprolol, and thioridazine) and bufuralol. Dextromethorphan exhibited the highest sensitivity to in vitro inhibition, whereas metoprolol was the least sensitive. In addition, when metoprolol was the substrate, inhibitors with structurally constrained amino moieties (clozapine, debrisoquine, harmine, quinidine, and yohimbine) exhibited at least a 5-fold decrease in inhibition potency when results were compared with those for dextromethorphan. Atypical inhibition kinetics were observed for these and other inhibitor-substrate pairings. In silico docking studies suggested that interactions with Glu216 and an adjacent hydrophobic binding pocket may influence substrate sensitivity and inhibition potency for CYP2D6. The in vivo sensitivities of the clinically relevant CYP2D6 substrates desipramine, dextromethorphan, and metoprolol were determined on the basis of literature drug-drug interaction (DDI) outcomes. Similar to the in vitro results, dextromethorphan exhibited the highest sensitivity to CYP2D6 inhibition in vivo. Finally, the magnitude of in vivo CYP2D6 DDIs caused by quinidine was predicted using desipramine, dextromethorphan, and metoprolol. Comparisons of the predictions with literature results indicated that the marked decrease in inhibition potency observed for the metoprolol-quinidine interaction in vitro translated to the in vivo situation.
authors: Pharmacokinetics and Drug Metabolism, Amgen, Inc., 1201 Amgen Court West, Seattle, WA 98119, USA.
authors: Brooke M
authors: BM
authors: VandenBrink
authors: Robert S
authors: RS
authors: Foti
authors: Dan A
authors: DA
authors: Rock
authors: Larry C
authors: LC
authors: Wienkers
authors: Jan L
authors: JL
authors: Wahlstrom
mesh_terms: D001665:Binding Sites / Q000502:physiology; D019389:Cytochrome P-450 CYP2D6 / Q000737:chemistry* / Q000378:metabolism*; D004347:Drug Interactions / Q000502:physiology*; D005544:Forecasting; D006801:Humans; D008862:Microsomes, Liver / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism*; D013379:Substrate Specificity / Q000502:physiology
chemical_list: D004364:Pharmaceutical Preparations; D019389:Cytochrome P-450 CYP2D6